Results of Studies Using pSivida Technologies in Glaucoma and Degenerative Eye Diseases to be Presented at Upcoming ARVO Meeting
Nine Presentations at ARVO to Feature pSivida Technologies
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV - News)(ASX:PVA - News), a leader in the development of back of the eye drug delivery systems, today announced that
two poster presentations will be made at the upcoming ARVO meeting on one of pSivida’s next generation bioerodible technologies for degenerative eye disease.
It marks a key step toward the ability to use pSivida’s bioerodible technologies to develop treatments for glaucoma and other degenerative eye diseases, diseases that affect millions of Americans.
“Development of Bioerodible Sustained Release Brimonidine Intraocular Device”
and
“Evaluation of a Single Intravitreal Injection of Extended Release Brimonidine Impregnated Device in a Rabbit Eye”
report successful pre-clinical results of the next generation Durasert™ devices as a means of delivering Brimonidine to the back of the eye over a three-month period.
“We are encouraged by the results of these studies,” stated Dr. Paul Ashton, President and CEO of pSivida.
“While glaucoma can be treated with daily or twice daily eye drops, patient compliance is an issue.
Long term sustained delivery directly to the target site has the potential to mark a major shift in the treatment of glaucoma and other degenerative eye diseases.”
Ashton noted that Durasert technology is also used in Iluvien® for the treatment of diabetic macular edema (DME), which has been licensed to Alimera Sciences.
A new drug application (NDA) for Iluvien is expected to be submitted to the FDA in this quarter and, if approved, will mark the first drug treatment for this disease.
Other Presentations on Durasert Technologies
In addition to the posters being presented on the bioerodible system,
there will be seven additional presentations on Durasert technologies, including Retisert® and Iluivien.
Dr. Ashton said
“In addition to the three presentations on studies sponsored by pSivida and its partners,
we are pleased that there are
six poster presentations
by independent researchers of additional studies involving pSivida’s technologies.
These will be delivered by doctors from well known institutions.”
ARVO is the largest research gathering for ophthalmologists and vision scientists in the world .The Association for Research in Vision and Ophthalmology, Inc. (ARVO) was founded in 1928. Its membership is comprised of more than 12,500 individuals from 70 countries. The membership is multidisciplinary and consists of both clinical and basic researchers. ARVO is based in Rockville, Maryland.
About pSivida Corp.
pSivida Corp is a world leader in the development of tiny, sustained release, drug delivery products that are administered by implantation, insertion or injection. We are using these systems to develop treatments for serious, unmet, medical needs. The Company’s lead development product, Iluvien, delivers fluocinolone acetonide (FA) for the treatment of DME. DME affects approximately 1m people in the US and is one of the leading causes of vision loss. Currently, there are no FDA approved drugs for this disease. Iluvien, formerly known as Medidur™ FA for DME, is licensed to Alimera, which is conducting fully-recruited Phase III clinical trials and has announced that it intends to file an NDA with the FDA in the second quarter of 2010. pSivida also has two products approved by the FDA: Retisert® for the treatment of posterior uveitis and Vitrasert® for the treatment of AIDS-related cytomegalovirus (CMV) retinitis. pSivida has licensed both of these products and the technologies underlying them to Bausch & Lomb Incorporated. pSivida has a worldwide collaborative research and license agreement with Pfizer under which Pfizer may develop additional ophthalmic products. In addition pSivida has a multiple of other products in development.
pSivida’s intellectual property portfolio consists of 62 patent families, over 100 granted patents, including patents accepted for issuance, and over 200 patent applications. pSivida conducts its operations from Boston in the United States and Malvern in the United Kingdom.
finance.yahoo.com |
